Analyzing Aktis Oncology (NASDAQ:AKTS) and Allogene Therapeutics (NASDAQ:ALLO)

Allogene Therapeutics (NASDAQ:ALLO) and Aktis Oncology (NASDAQ:AKTS) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, risk, earnings and dividends.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Allogene Therapeutics and Aktis Oncology, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Allogene Therapeutics	1	3	8	2	2.79
Aktis Oncology	1	0	9	1	2.91

Allogene Therapeutics presently has a consensus target price of $8.30, indicating a potential upside of 790.65%. Aktis Oncology has a consensus target price of $35.62, indicating a potential upside of 104.15%. Given Allogene Therapeutics’ higher possible upside, equities analysts clearly believe Allogene Therapeutics is more favorable than Aktis Oncology.

Institutional & Insider Ownership

83.6% of Allogene Therapeutics shares are owned by institutional investors. Comparatively, 28.8% of Aktis Oncology shares are owned by institutional investors. 13.2% of Allogene Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Allogene Therapeutics and Aktis Oncology’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Allogene Therapeutics	N/A	-49.84%	-37.25%
Aktis Oncology	N/A	N/A	N/A

Valuation and Earnings

This table compares Allogene Therapeutics and Aktis Oncology”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Allogene Therapeutics	$20,000.00	16,143.77	-$190.89 million	($0.63)	-1.48
Aktis Oncology	$6.50 million	144.30	-$63.73 million	($0.82)	-21.28

Aktis Oncology has higher revenue and earnings than Allogene Therapeutics. Aktis Oncology is trading at a lower price-to-earnings ratio than Allogene Therapeutics, indicating that it is currently the more affordable of the two stocks.

About Allogene Therapeutics

Allogene Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing allogeneic, or “off-the-shelf,” CAR T cell therapies for cancer. Unlike conventional autologous CAR T treatments, which are manufactured from an individual patient’s own cells, Allogene’s approach uses healthy donor cells that can potentially be produced in advance and administered more quickly. The company’s investigational pipeline has included cemacabtagene ansegedleucel (cema-cel, formerly ALLO-501A) for certain patients with large B-cell lymphoma, as well as other allogeneic CAR T candidates being studied in blood cancers such as multiple myeloma and in solid tumors, including renal cell carcinoma.

About Aktis Oncology

Aktis Oncology, Inc. is a clinical-stage biotechnology company developing targeted radiopharmaceuticals for solid tumors. Its approach uses small protein-based molecules designed to bind cancer-associated targets and deliver radioactive payloads to tumor cells. The company’s pipeline includes investigational programs directed at targets found on solid tumors, including Nectin-4. These candidates are being developed for potential use in patients with advanced cancers; they are not approved for commercial use.